T-Therapeutics raises $133 million from Sanofi, J&J, Merck KGaA and Eli Lilly for TCR cancer and autoimmune programs
read at Endpoints ↗DealPositive
T-Therapeutics, a UK biotech focused on T-cell receptor therapies for cancer and autoimmune diseases, announced it has raised $133 million in financing.
The round is led by Sanofi with participation from Johnson & Johnson, Merck KGaA and Eli Lilly, showing strong interest from major pharma in the company’s platform.
The new capital will be used to advance TCR programs targeting oncology and autoimmune indications, moving the pipeline forward.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “T-Therapeutics secures $133M for cancer, autoimmune TCRs”
read at Endpoints ↗84 words · retrieved 1h ago
comments(0)
5-min edit window · permanent after that